000137076 001__ 137076
000137076 005__ 20240321220202.0
000137076 0247_ $$2doi$$a10.3233/JAD-130509
000137076 0247_ $$2pmid$$apmid:23948916
000137076 0247_ $$2ISSN$$a1387-2877
000137076 0247_ $$2ISSN$$a1875-8908
000137076 037__ $$aDZNE-2020-03398
000137076 041__ $$aEnglish
000137076 082__ $$a610
000137076 1001_ $$0P:(DE-2719)9000311$$aTaverna, Mara$$b0$$eFirst author$$udzne
000137076 245__ $$aA new sandwich immunoassay for detection of the α-secretase cleaved, soluble amyloid-β protein precursor in cerebrospinal fluid and serum.
000137076 260__ $$aAmsterdam$$bIOS Press$$c2013
000137076 264_1 $$2Crossref$$3print$$bIOS Press$$c2013-10-10
000137076 3367_ $$2DRIVER$$aarticle
000137076 3367_ $$2DataCite$$aOutput Types/Journal article
000137076 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710945633_2067
000137076 3367_ $$2BibTeX$$aARTICLE
000137076 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137076 3367_ $$00$$2EndNote$$aJournal Article
000137076 520__ $$aAlzheimer's disease (AD) is the most common neurodegenerative disorder. Frequently used diagnostic biomarkers are amyloid-β42 (Aβ42), tau, and phospho-tau, which are measured in cerebrospinal fluid (CSF), and allow a reasonable, but not full, separation of AD patients and controls. Besides Aβ42, additional proteolytic cleavage products of the amyloid-β protein precursor (AβPP) have been investigated as potential biomarkers. This includes the α-secretase cleaved soluble AβPP ectodomain (sAβPPα). However, some studies found a reduction of sAβPPα, whereas other studies reported an increase of sAβPPα in the CSF of AD patients. The divergent findings may result from the detection of sAβPPα with antibodies, such as 6E10, which do not exclusively detect sAβPPα, but also the alternative β-secretase cleavage product sAβPPβ'. Here, we used the sAβPPα-specific antibody 14D6 and developed an ELISA-like sandwich immunoassay. The assay specifically detected sAβPPα in cell culture supernatants, in human CSF and even in serum, which is more readily accessible than CSF. The assay was used to analyze sAβPPα levels in CSF and serum of AD patients and controls. The assay detected a mild, but significant increase in sAβPPα in the CSF of AD patients compared to non-demented controls, while a mild reduction was observed in serum. The 14D6 assay in CSF allowed a better separation of AD patients from controls compared to the 6E10 antibody. Taken together, the new assay is widely applicable for specific sAβPPα measurement in culture media, CSF, and serum.
000137076 536__ $$0G:(DE-HGF)POF3-342$$a342 - Disease Mechanisms and Model Systems (POF3-342)$$cPOF3-342$$fPOF III$$x0
000137076 588__ $$aDataset connected to CrossRef, PubMed,
000137076 650_7 $$2NLM Chemicals$$aAmyloid beta-Protein Precursor
000137076 650_7 $$2NLM Chemicals$$aBiomarkers
000137076 650_7 $$0EC 3.4.-$$2NLM Chemicals$$aAmyloid Precursor Protein Secretases
000137076 650_2 $$2MeSH$$aAmino Acid Sequence
000137076 650_2 $$2MeSH$$aAmyloid Precursor Protein Secretases: blood
000137076 650_2 $$2MeSH$$aAmyloid Precursor Protein Secretases: cerebrospinal fluid
000137076 650_2 $$2MeSH$$aAmyloid Precursor Protein Secretases: genetics
000137076 650_2 $$2MeSH$$aAmyloid beta-Protein Precursor: blood
000137076 650_2 $$2MeSH$$aAmyloid beta-Protein Precursor: cerebrospinal fluid
000137076 650_2 $$2MeSH$$aAmyloid beta-Protein Precursor: genetics
000137076 650_2 $$2MeSH$$aBiomarkers: blood
000137076 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000137076 650_2 $$2MeSH$$aCell Line, Tumor
000137076 650_2 $$2MeSH$$aEnzyme-Linked Immunosorbent Assay: trends
000137076 650_2 $$2MeSH$$aFemale
000137076 650_2 $$2MeSH$$aHumans
000137076 650_2 $$2MeSH$$aMale
000137076 650_2 $$2MeSH$$aMolecular Sequence Data
000137076 650_2 $$2MeSH$$aRegistries
000137076 7001_ $$0P:(DE-HGF)0$$aStraub, Tobias$$b1
000137076 7001_ $$0P:(DE-HGF)0$$aHampel, Harald$$b2
000137076 7001_ $$0P:(DE-HGF)0$$aRujescu, Dan$$b3
000137076 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan F$$b4$$eLast author$$udzne
000137076 77318 $$2Crossref$$3journal-article$$a10.3233/jad-130509$$b : IOS Press, 2013-10-10$$n4$$p667-678$$tJournal of Alzheimer's Disease$$v37$$x1875-8908$$y2013
000137076 773__ $$0PERI:(DE-600)2070772-1$$a10.3233/JAD-130509$$gVol. 37, no. 4, p. 667 - 678$$n4$$p667-678$$q37:4<667 - 678$$tJournal of Alzheimer's disease$$v37$$x1875-8908$$y2013
000137076 8564_ $$uhttps://pub.dzne.de/record/137076/files/DZNE-2020-03398_Restricted.pdf
000137076 8564_ $$uhttps://pub.dzne.de/record/137076/files/DZNE-2020-03398_Restricted.pdf?subformat=pdfa$$xpdfa
000137076 909CO $$ooai:pub.dzne.de:137076$$pVDB
000137076 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000311$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000137076 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000137076 9131_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000137076 9141_ $$y2013
000137076 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ALZHEIMERS DIS : 2017
000137076 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137076 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137076 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137076 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000137076 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000137076 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000137076 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137076 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137076 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000137076 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137076 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000137076 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000137076 980__ $$ajournal
000137076 980__ $$aVDB
000137076 980__ $$aI:(DE-2719)1110006
000137076 980__ $$aUNRESTRICTED